SCHEMBL13577144

SCHEMBL13577144

COc1cccc(C(C)Oc2ccc(Cl)c(N)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASR P41180 6/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ AOC3 Q16853 3/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ HTR1A P08908 1/20 0.39
▸ ADRA2B P18089 1/20 0.39
▸ ADRA2C P18825 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ HRH2 P25021 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ HTR2C P28335 1/20 0.39
▸ HRH1 P35367 1/20 0.39
▸ OPRM1 P35372 1/20 0.39
▸ DRD3 P35462 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ HTR5A P47898 1/20 0.39
▸ HTR6 P50406 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13577172 0.87 SMN1; SMN2 (0.40) SMN1; SMN2ALDH1A1CYP3A4HTR2AHTR6
SCHEMBL13577156 0.86 DHFR (0.47) SMN1; SMN2AOC3HTR1AHTR2AHTR2C
SCHEMBL13577145 0.85 ALDH1A1 (0.41) SMN1; SMN2L3MBTL1ALDH1A1CYP3A4MEN1
SCHEMBL13577129 0.84 ALOX5 (0.47) —
SCHEMBL13577006 0.84 ALOX5 (0.47) —
SCHEMBL13577130 0.84 ALOX5 (0.47) —
SCHEMBL13577139 0.83 SLC6A4 (0.43) AOC3HTR2CHTR6
SCHEMBL13577148 0.80 ADAMTS4 (0.47) HTR2AHTR2CHTR2BHTR6
SCHEMBL110854 0.78 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1CYP3A4MEN1KMT2A
SCHEMBL13577142 0.78 MET (0.42) SMN1; SMN2HTR2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040693-B2 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 — — US disclosed
US-9040693-B2 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 — — US disclosed
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 — — US disclosed
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF SHBG, CYP19A1, NR5A1 CASR 4129/4885SMN1; SMN2 4008/4885AOC3 696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback